Sources, specificities, and isotypes of antibodies used in study
| mAb . | Specificity . | Isotype . | Source . |
|---|---|---|---|
| 2H7 | CD20 | IgG2b | Serotec, Oxford, United Kingdom |
| IF5 | CD20 | IgG2a | ECACC Hybridoma |
| B1 | CD20 | IgG2a | Coulter, Miami, FL |
| HI47 | CD20 | IgG3 | ECACC Hybridoma |
| Rituximab | CD20 | Chimeric Hu Fc | IDEC, San Francisco, CA |
| AT80 | CD20 | IgG1 | In-house |
| LT20 | CD20 | IgG1 | In-house |
| MB1/7 | CD37 | IgG1 | Richard Miller30 |
| WR17 | CD37 | IgG2a | Keith Moore31 |
| AT13/5 | CD38 | IgG1 | In-house |
| IB4 | CD38 | IgG2a | Fabio Malavasi32 |
| F3.3 | MHC II | IgG1 | In-house |
| A9-1 | MHC II | IgG2a | In-house |
| CAMPATH-1H | CD52 | Chimeric Hu Fc | Geoff Hale33 |
| mAb . | Specificity . | Isotype . | Source . |
|---|---|---|---|
| 2H7 | CD20 | IgG2b | Serotec, Oxford, United Kingdom |
| IF5 | CD20 | IgG2a | ECACC Hybridoma |
| B1 | CD20 | IgG2a | Coulter, Miami, FL |
| HI47 | CD20 | IgG3 | ECACC Hybridoma |
| Rituximab | CD20 | Chimeric Hu Fc | IDEC, San Francisco, CA |
| AT80 | CD20 | IgG1 | In-house |
| LT20 | CD20 | IgG1 | In-house |
| MB1/7 | CD37 | IgG1 | Richard Miller30 |
| WR17 | CD37 | IgG2a | Keith Moore31 |
| AT13/5 | CD38 | IgG1 | In-house |
| IB4 | CD38 | IgG2a | Fabio Malavasi32 |
| F3.3 | MHC II | IgG1 | In-house |
| A9-1 | MHC II | IgG2a | In-house |
| CAMPATH-1H | CD52 | Chimeric Hu Fc | Geoff Hale33 |